Geisinger Health System’s $0 co-pay drug program for its chronically ill employee population is associated with positive cost savings and a 5-year return-on-investment of approximately 1.8.
James M. Pitcavage, MSPH
Advertisement
Articles by James M. Pitcavage, MSPH
Advertisement
Latest Updated Articles
- The Value of Value-Based Insurance Design: Savings From Eliminating Drug Co-Payments
Published: February 16th 2016 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Novel Machine Learning Model Improves MASLD Detection in Type 2 Diabetes
2
Accountable Care: Not Just for the Healthiest Patients
3
Increased Risk of Recurrence in NSCLC Found After Preoperative PTNB
4
Real-World Data Highlight Value of NOTCH1 Screening in CLL
5
